Cardiomyopathy Tissue Bank in a Cancer Population
The goal of this laboratory research study is to collect and store blood and tissue from patients who have a diagnosis of heart disease and may be at a high risk for the development of heart failure. This blood may be used in the future to identify genes that may play a role in developing congestive heart failure (CHF) from chemotherapy or other sources.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Cardiomyopathy Tissue Bank in a Cancer Population|
- Baseline Patient Demographic Information (age, sex, race) [ Time Frame: One time visit. ] [ Designated as safety issue: No ]
- Identification biological markers predisposing cancer patients to development of chemotherapy-induced congestive heart failure [ Time Frame: One time visit for collection of blood and tissue samples. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood and tissue collection. This blood may be studied in the future to try to find possible genetic or biochemical markers that may be the cause of CHF.
|Study Start Date:||December 2002|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
|Heart Disease Patients||
Procedure: Blood Sample
One time blood draw of 2 teaspoons.
You will have a one time blood draw of 2 teaspoons of blood for use in future research. This blood may be studied in the future to try to find possible genetic or biochemical markers that may be the cause of CHF. Your blood will be drawn either on an outpatient basis or during a routine visit to the hospital. If you already have a central line or an IV placed, the blood will be drawn at these sites to decrease the pain and discomfort of the blood draw. The information obtained in this study will not be put into your medical records.
This is an investigational study. All will be enrolled at MD Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00500734
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Jean-Bernard Durand, MD||M.D. Anderson Cancer Center|